Primex Pharma gets global rights to Advicenne anaesthesiology candidate

Swiss drugmaker Primex Pharmaceuticals has signed a deal with France-based Advicenne to acquire global rights for the latter’s lead product, an advanced oral pharmaceutical candidate for pediatric anesthesiology. The market potential is evaluated as “hundreds of millions of euros.”

This oral solution is dedicated to pediatric anesthesiology. Nearly 10,000 patients have already been successfully treated by the university hospital at Amiens, which collaborated with Advicenne.

With this acquisition, financial terms of which were not disclosed, Primex Pharmaceuticals expands its anesthesiology portfolio with a unique product that will be distributed through Primex’ existing channels and new partners, which will be appointed in all other markets.